Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
42
PCRX Quote, Financials, Valuation and Earnings
Last price:
$24.42
Seasonality move
:
13.08%
Day range:
$25.85 - $26.37
52-week range:
$18.17 - $27.64
Dividend yield:
0%
P/E ratio:
54.83x
P/S ratio:
1.58x
P/B ratio:
1.45x
Volume:
722.3K
Avg. volume:
791K
1-year change:
37.37%
Market cap:
$1.1B
Revenue:
$701M
EPS (TTM):
$0.45
Analysts' Opinion
-
Consensus RatingPacira Biosciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.71, Pacira Biosciences, Inc. has an estimated upside of 21.48% from its current price of $25.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $25.88.
Fair Value
-
According to the consensus of 5 analysts, Pacira Biosciences, Inc. has 21.48% upside to fair value with a price target of $29.71 per share.
PCRX vs. S&P 500
-
Over the past 5 trading days, Pacira Biosciences, Inc. has underperformed the S&P 500 by -5.02% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pacira Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pacira Biosciences, Inc. has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Pacira Biosciences, Inc. reported revenues of $179.5M.
Earnings Growth
-
Pacira Biosciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Pacira Biosciences, Inc. reported earnings per share of $0.12.
Enterprise value:
1.2B
EV / Invested capital:
--
Price / LTM sales:
1.58x
EV / EBIT:
20.52x
EV / Revenue:
1.72x
PEG ratio (5yr expected):
--
EV / Free cash flow:
9.91x
Price / Operating cash flow:
9.13x
Enterprise value / EBITDA:
8.16x
Gross Profit (TTM):
$510.2M
Return On Assets:
1.43%
Net Income Margin (TTM):
2.99%
Return On Equity:
2.81%
Return On Invested Capital:
1.58%
Operating Margin:
7.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $665.7M | $695M | $716.8M | $168.6M | $179.5M | |
| Gross Profit | $409.5M | $459.4M | $510.2M | $115.4M | $130.9M | |
| Operating Income | $67.6M | $102M | $60M | $22M | $13.2M | |
| EBITDA | $155.1M | $178M | $150.9M | $42.2M | $34.3M | |
| Diluted EPS | $0.08 | -$2.05 | $0.45 | -$3.11 | $0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $822.4M | $533.4M | $447.3M | $690M | $562.8M | |
| Total Assets | $1.4B | $1.7B | $1.5B | $1.5B | $1.3B | |
| Current Liabilities | $225.8M | $131.5M | $93.7M | $306.4M | $107.1M | |
| Total Liabilities | $637.4M | $964.2M | $702.9M | $772.1M | $570.4M | |
| Total Equity | $718.6M | $770.1M | $831.6M | $749.6M | $727.2M | |
| Total Debt | $548.7M | $813.3M | $581.7M | $635.2M | $415.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $149.1M | $203.8M | $141.4M | $53.9M | $60.8M | |
| Cash From Investing | $80.4M | -$74.5M | $79.8M | -$52.2M | $43.6M | |
| Cash From Financing | -$239.8M | $17.5M | -$319.9M | -$2.8M | -$257.5M | |
| Free Cash Flow | $130.2M | $193.5M | $124.2M | $49.8M | $57M | |
PCRX
Sector
Market Cap
$1.1B
$28.2M
Price % of 52-Week High
88.5%
50.98%
Dividend Yield
0%
0%
Shareholder Yield
12.85%
-1.55%
1-Year Price Total Return
33.44%
-17.58%
Beta (5-Year)
0.224
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$26.08
200-day SMA
Buy
Level
$24.51
Bollinger Bands (100)
Buy
Level
22.85 - 26.33
Chaikin Money Flow
Sell
Level
-1.5M
20-day SMA
Buy
Level
$25.62
Relative Strength Index (RSI14)
Buy
Level
56.51
ADX Line
Buy
Level
17.46
Williams %R
Buy
Level
-91.2159
50-day SMA
Buy
Level
$23.88
MACD (12, 26)
Buy
Level
7.16
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
1.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.483)
Buy
CA Score
(Annual)
Level (0.1158)
Buy
Beneish M-Score
(Annual)
Level (-3.4828)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.5187)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Stock Forecast FAQ
In the current month, PCRX has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The PCRX average analyst price target in the past 3 months is $29.71.
-
Where Will Pacira Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pacira Biosciences, Inc. share price will rise to $29.71 per share over the next 12 months.
-
What Do Analysts Say About Pacira Biosciences, Inc.?
Analysts are divided on their view about Pacira Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pacira Biosciences, Inc. is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Pacira Biosciences, Inc.'s Price Target?
The price target for Pacira Biosciences, Inc. over the next 1-year time period is forecast to be $29.71 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is PCRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pacira Biosciences, Inc. is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PCRX?
You can purchase shares of Pacira Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pacira Biosciences, Inc. shares.
-
What Is The Pacira Biosciences, Inc. Share Price Today?
Pacira Biosciences, Inc. was last trading at $24.42 per share. This represents the most recent stock quote for Pacira Biosciences, Inc.. Yesterday, Pacira Biosciences, Inc. closed at $25.88 per share.
-
How To Buy Pacira Biosciences, Inc. Stock Online?
In order to purchase Pacira Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PCRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PCRX
Sector
P/E ratio
54.83x
24.09x
PEG ratio
--
-0.01x
P/B ratio
1.45x
1.81x
Price / LTM sales
1.58x
1.59x
Growth Metrics
PCRX
Sector
Revenue growth
6.49%
4.68%
Earnings growth
103.93%
11.06%
Revenue (5-year growth)
10.73%
6.45%
Earnings forecast
$0.90
-$0.18
Profitability
PCRX
Sector
Profitability FY 2024
$473.3M
$3.6M
Return on invested capital
1.58%
-31.84%
Return on assets
1.43%
-28.18%
Return on equity
2.81%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
PCRX
Sector
Total cash
$246.3M
$26.3M
Short term investments
$207.8M
$26M
Total assets
$1.6B
$76.7M
Long term debt
$415.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
